SCHEMBL30748787

SCHEMBL30748787

CNc1nc(CO)nc2c1C(C)(C)C(=O)N2c1ccc(N2CCOCC2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.36
JAK1 P23458 3/20 0.36
JAK3 P52333 2/20 0.36
MAPT P10636 7/20 0.35
MAPK1 P28482 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PIK3CA P42336 2/20 0.35
GAA P10253 1/20 0.34
PIK3CB P42338 1/20 0.34
LRRK2 Q5S007 1/20 0.34
SYK P43405 3/20 0.34
JAK2 O60674 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749038 0.90 ADORA3 (0.39) L3MBTL1JAK1JAK3MAPTMAPK1
SCHEMBL30748933 0.90 SYK (0.40) L3MBTL1JAK1JAK3MAPTMAPK1
SCHEMBL30748952 0.88 SYK (0.37) L3MBTL1JAK1JAK3MAPTALDH1A1
SCHEMBL30749016 0.87 SYK (0.36) L3MBTL1JAK1JAK3ALDH1A1SYK
SCHEMBL30748754 0.86 XDH (0.36) L3MBTL1MAPTMAPK1KDM4EMEN1
SCHEMBL30749040 0.85 TRPV1 (0.38) MAPTALDH1A1LRRK2SYKJAK2
SCHEMBL31691354 0.84 AGXT (0.33) L3MBTL1JAK1JAK3MAPTMAPK1
SCHEMBL30748722 0.80 TTBK1 (0.38) L3MBTL1JAK3MAPTMAPK1KDM4E
SCHEMBL30749139 0.79 MAOB (0.41) JAK3ALDH1A1ALOX15HSD17B10GAA
SCHEMBL30748831 0.79 HRH3 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT L3MBTL1 517/4885JAK1 2335/4885JAK3 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.